Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any hypertrophic cardiomyopathy in which the cause of the disease is a mutation in the MYL3 gene.
Features include always present findings: T-wave inversion, Thickened heart muscle (hypertrophic cardiomyopathy), and Thickened left heart wall (left ventricular hypertrophy); and common findings: Left atrial enlargement. 13 total HPO annotations.
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 11:55 AM UTC
Online Mendelian Inheritance in Man
Organ System | Phenotype Count | Example Features |
|---|---|---|
Heart and blood vessels | 10 | Ventricular fibrillation, Cardiac arrest, Reduced left ventricular ejection fraction |
Lungs and breathing | 1 | Exertional dyspnea |
MYL3 encodes myosin light chain 3 (195 aa). Regulatory light chain of myosin. Does not bind calcium Highest expression in Heart Left Ventricle (3,734 TPM) and Muscle Skeletal (803.3 TPM).
Hypertrophic cardiomyopathy 8 is associated with mutations in the MYL3 gene on chromosome 3.
MYL3 is classified as a druggable target with score 2.5.
Genetic testing for MYL3 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for hypertrophic cardiomyopathy 8 has been reported in the published literature.
Phenotype severity distribution: 3 always present features, 1 common feature.
No clinical trials have been registered for hypertrophic cardiomyopathy 8.
231 publications have been identified in PubMed for hypertrophic cardiomyopathy 8. Research spans Epidemiology / Natural History (26%), Clinical Trial Publication (22%), and Review / Meta-Analysis (14%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 59 | 26% |
Clinical study results | 51 | 22% |
Research summaries | 33 | 14% |
Laboratory research | 32 | 14% |
Testing and diagnosis research | 29 | 13% |
Other research | 13 | 6% |
New treatment approaches | 8 | 3% |
Patient case studies | 6 | 3% |
Fahim M (2026). [PMID: 41672217](https://pubmed.ncbi.nlm.nih.gov/41672217/). *Am J Cardiol*. [Review / Meta-Analysis]
Fell J (2026). [PMID: 41988707](https://pubmed.ncbi.nlm.nih.gov/41988707/). *Circulation*. [Gene Therapy / Novel Therapeutics]
Minette F (2026). [PMID: 41081838](https://pubmed.ncbi.nlm.nih.gov/41081838/). *Clin Res Cardiol*. [Epidemiology / Natural History]
Vissing CR (2026). [PMID: 41800474](https://pubmed.ncbi.nlm.nih.gov/41800474/). *Circulation*. [Epidemiology / Natural History]
Heeringa TJP (2026). [PMID: 40878834](https://pubmed.ncbi.nlm.nih.gov/40878834/). *Eur Heart J*. [Clinical Trial Publication]
Dababneh SF (2026). [PMID: 41893039](https://pubmed.ncbi.nlm.nih.gov/41893039/). *J Pers Med*. [Basic Science / Preclinical]
Saberi S (2026). [PMID: 41498737](https://pubmed.ncbi.nlm.nih.gov/41498737/). *J Am Coll Cardiol*. [Other]
Suwa K (2026). [PMID: 41129543](https://pubmed.ncbi.nlm.nih.gov/41129543/). *J Magn Reson Imaging*. [Clinical Trial Publication]
Patel N (2026). [PMID: 40704931](https://pubmed.ncbi.nlm.nih.gov/40704931/). *Mayo Clin Proc*. [Clinical Trial Publication]
Obayashi Y (2026). [PMID: 41636023](https://pubmed.ncbi.nlm.nih.gov/41636023/). *Circ Heart Fail*. [Diagnostic / Biomarker]